This week, the FDA stepped in to ease parents' minds by approving an RSV vaccine to protect newborns.
It's important because it's considered part of the tripledemic of flu, COVID and RSV expected to hit this fall and winter. Each year in the U.S., about 2.1 million kids younger than five must visit their doctor because of RSV. Between 58,000 and 80,000 are hospitalized, and 100 to 300 children younger than five die yearly.
Edwards said the maternal RSV vaccine coming mid-October is exciting and hopeful, two words that are never associated with RSV.RSV attacks the lungs and can be life-threatening to young children and adults over 60, but especially infants. Edwards said hospitalized RSV cases last fall and winter were practically unmanageable.
The new vaccine, made by Pfizer, will be given to mothers late in their pregnancy, which protects newborns for the first six months of their lives. Akron Children's Hospital Chief Academic Officer Dr. Michael Forbes called the vaccine a game changer. Vaccine hesitancy from expecting mothers remains an issue physicians are battling post-COVID-19 pandemic. Edwards hopes soon-to-be-mothers talk to their OBGYNs and learn the benefits of passive immunity.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves 1st maternal RSV vaccine to help protect infantsThe U.S. Food and Drug Administration has approved the first maternal vaccine intended to help protect newborns against respiratory syncytial virus (RSV).
Read more »
US FDA approves Pfizer's maternal RSV vaccine to protect infantsThe U.S. Food and Drug Administration on Monday approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies.
Read more »
FDA approves first RSV vaccine for pregnancy to protect newbornsExpectant parents could soon have another new option this fall to protect their newborns from RSV, the most common cause of hospitalization in American infants.
Read more »
FDA approves Pfizer maternal RSV vaccine for infantsPfizer hopes that its respiratory syncytial virus vaccine will be available to the public by the end of October or the beginning of November.
Read more »
Pfizer maternal RSV vaccine gets FDA approvalNew shot designed to protect babies against leading cause of hospitalization is expected to be available this fall.
Read more »